If you had told Robert L. Meyer, when he was a law student at Columbia University, that in the 21st century he would be talking to people about a natural product that effectively and safely reduces inflammation for sufferers of chronic inflammatory disorders, he would probably have thought you were mad.

But today Meyer runs Pharmalink International Limited, a company that owns the intellectual property assets associated with the commercial nutraceutical product, Lyprinol®, derived from the New Zealand green-lipped mussel (Perna canaliculus).